119 related articles for article (PubMed ID: 9156052)
1. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate: what's new?
Faustini-Fustini M
Clin Endocrinol (Oxf); 1997 Mar; 46(3):378. PubMed ID: 9156052
[No Abstract] [Full Text] [Related]
2. Pituitary Apoplexy After Initial Leuprolide Injection.
Fabiano AJ; George S
World Neurosurg; 2016 Nov; 95():616.e7-616.e9. PubMed ID: 27586180
[TBL] [Abstract][Full Text] [Related]
3. Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.
Morsi A; Jamal S; Silverberg JD
Clin Endocrinol (Oxf); 1996 Jan; 44(1):121-4. PubMed ID: 8706284
[TBL] [Abstract][Full Text] [Related]
4. Pituitary apoplexy after leuprolide.
Davis A; Goel S; Picolos M; Wang M; Lavis V
Pituitary; 2006; 9(3):263-5. PubMed ID: 16832587
[TBL] [Abstract][Full Text] [Related]
5. Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with gonadotropin-secreting pituitary adenoma.
Sasagawa Y; Tachibana O; Nakagawa A; Koya D; Iizuka H
J Clin Neurosci; 2015 Mar; 22(3):601-3. PubMed ID: 25455737
[TBL] [Abstract][Full Text] [Related]
6. Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.
Tanios G; Mungo NA; Kapila A; Bajaj K
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710301
[TBL] [Abstract][Full Text] [Related]
7. A Case of Pituitary Apoplexy Following Leuprolide Injection for Prostate Cancer.
Kim KW; Chee S; Sunkara N; Baker MH
R I Med J (2013); 2024 Feb; 107(2):7-9. PubMed ID: 38285742
[TBL] [Abstract][Full Text] [Related]
8. Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.
Huang TY; Lin JP; Lieu AS; Chen YT; Chen HS; Jang MY; Shen JT; Wu WJ; Huang SP; Juan YS
World J Surg Oncol; 2013 Oct; 11():254. PubMed ID: 24088191
[TBL] [Abstract][Full Text] [Related]
9. The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy.
Babbo A; Kalapurakal GT; Liu B; Bajramovic S; Chandler JP; Garnett J; Kalapurakal JA
Int Urol Nephrol; 2014 Sep; 46(9):1775-8. PubMed ID: 24705727
[TBL] [Abstract][Full Text] [Related]
10. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma.
Wiechert A; Tüting T; Bieber T; Haidl G; Wenzel J
Br J Dermatol; 2008 Jul; 159(1):231-3. PubMed ID: 18476960
[No Abstract] [Full Text] [Related]
11. Rapid onset of pituitary apoplexy after goserelin implant for prostate cancer: need for heightened awareness.
Eaton HJ; Phillips PJ; Hanieh A; Cooper J; Bolt J; Torpy DJ
Intern Med J; 2001 Jul; 31(5):313-4. PubMed ID: 11512605
[No Abstract] [Full Text] [Related]
12. Pituitary apoplexy induced by gonadotropin-releasing hormone (GnRH) agonist administration for treatment of prostate cancer: a systematic review.
Raj R; Elshimy G; Jacob A; Arya PVA; Unnikrishnan DC; Correa R; Myint ZW
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2337-2347. PubMed ID: 34156518
[TBL] [Abstract][Full Text] [Related]
13. Pituitary apoplexy induced by triptorelin in patient with prostate cancer.
Guerrero-Pérez F; Marengo AP; Planas-Vilaseca A; Flores-Escobar V; Villabona-Artero C
Endocrinol Nutr; 2015 Oct; 62(8):411-2. PubMed ID: 26184059
[No Abstract] [Full Text] [Related]
14. Dermatitis herpetiformis associated with administration of a gonadotropin-releasing hormone analog.
Yu SS; Connolly MK; Berger TG; McCalmont TH
J Am Acad Dermatol; 2006 Feb; 54(2 Suppl):S58-9. PubMed ID: 16428002
[No Abstract] [Full Text] [Related]
15. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
16. What should I know about Lupron Depot for treating prostate cancer?
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
[No Abstract] [Full Text] [Related]
17. Knowing all the side effects.
Dodd BA
RN; 1997 Jan; 60(1):68. PubMed ID: 9016171
[No Abstract] [Full Text] [Related]
18. Interstitial pneumonitis related to leuprorelin acetate and flutamide.
Azuma T; Kurimoto S; Mikami K; Oshi M
J Urol; 1999 Jan; 161(1):221. PubMed ID: 10037405
[No Abstract] [Full Text] [Related]
19. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
20. Leuprolide causes pure red cell aplasia.
Maeda H; Arai Y; Aoki Y; Okubo K; Okada T; Ueda Y
J Urol; 1998 Aug; 160(2):501. PubMed ID: 9679912
[No Abstract] [Full Text] [Related]
[Next] [New Search]
